|The CardioGenomic Plus™ Profile uses genomic testing to identify the risk of genetic susceptibility to cardiac related diseases and conditions. This test evaluates genetic variations, called single nucleotide polymorphisms (SNPs) in genes that modulate blood pressure regulation, lipid balance, nutrient metabolism, inflammation, and oxidative stress.
This test uncovers potential genetic susceptibility to:
- Myocardial infarction
- Endothelial dysfunction
The CardioGenomic Plus™ Profile evaluations include:
Cholesterol Regulation and Atherosclerosis
- ApoE (apolipoprotein E)
- CETP (cholesteryl ester transfer protein)
- SELE (selectin E)
These genes affect how the body breaks down and clears fats and how cholesterol is processed. They also affect lipid balance, plaque formation, and blood vessel integrity and function.
- MTHFR (methylenetetrahydrofolate reductase)
Polymorphisms of this enzyme can disrupt the metabolism of homocysteine, resulting in its accumulation as well as impaired methylation. The presence of these SNPs can increase risk of cardiovascular disease, blood vessel damage, thrombosis (blood clots), stroke, and degenerative aging.
- GNB3 (guanine nucleotide-binding protein)
- AGTR1 (angiotensin II receptor-1)
Polymorphisms of these genes are associated with blood vessel constriction, sodium and water retention, obesity, and increased susceptibility to hypertension.
- Factor 2 (prothrombin)
- Factor 5 (Leiden)
- PAI-1 (Plasminogen activator inhibitor-1)
- GP3a (Glycoprotein 3)
These genetic variants can over-activate blood clotting processes, increasing the risk of sudden cardiac events such as thrombosis, heart attacks, and strokes.